X

Trial Profile

Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lixisenatide (Primary)
Indications Parkinson's disease
Focus Proof of concept; Therapeutic Use
Acronyms LixiPark

Most Recent Events

27 Aug 2023 According to The International Parkinson and Movement Disorder Society media release, data from this study released at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark.
27 Aug 2023 Results published in the Media Release
19 Jun 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com